In our study, we applied the VS study using EGFR-TK receptor-gefitinib complex structure against a diversity set of 350,000 small-molecule compounds (ChemDiv Library DC0, accessed Sep 08, 2022) in order to identify new EGFR inhibitors as potential anti-cancer agents. The gene discussed is EGFR; the disease is cancer.